GCIG Clinical Trials By Lead Cooperative Group

Disease Site Trialsort descending Trial Number Trial Description Contact Person Trial Status Lead Cooperative Group Participating Groups
Cervical 55994

ClinicalTrials.gov Identifier: NCT00039338

Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer sgreggi Closed to Recruitment EORTC-GCG EORTC-GCG
Ovarian AGO – OVAR OP.3 (LION)

ClinicalTrials.gov Identifier: NCT00712218

Lymphadenectomy In Ovarian Neoplasms pharter Completed AGO AGO-AUST, BGOG, KGOG, MaNGO, MITO
Recurrent Ovarian AGO-OVAR 2.21

ClinicalTrials.gov Identifier: NCT01837251

A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carbolatin/pegylated liposomal doxorubin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer jpfisterer Follow Up AGO AGO-AUST, ANZGOG, GINECO, SGCTG
Recurrent Ovarian AGO-OVAR OP.4/DESKTOP III

ClinicalTrials.gov Identifier: NCT01166737

A randomized trial evaluating cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer pharter Follow Up AGO AGO-AUST, BGOG, GEICO, GINECO, KGOG, MaNGO, MITO, NSGO, SGOG

ClinicalTrials.gov Identifier: NCT02828618

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST) smahner Recruiting AGO GINECO, MaNGO, NSGO
Ovarian AGO-OVAR12 (BI 1199.15)

ClinicalTrials.gov Identifier: NCT01015118

Multicenter, randomised, double-blind phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer pharter Completed AGO AGO-AUST, BGOG, DGOG, GEICO, GINECO, MaNGO, MITO, NSGO
Ovarian AGO-OVAR16 (VEG110655)

ClinicalTrials.gov Identifier: NCT00866697 

A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy versus Placebo in Women who have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer gelser Completed AGO AGO-AUST, ANZGOG, BGOG, GEICO, GINECO, ICORG, JGOG, KGOG, MaNGO, MITO, NSGO
Ovarian AGO-OVAR17

ClinicalTrials.gov Identifier: NCT01462890

Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST) jpfisterer Follow Up AGO GINECO, NSGO

ClinicalTrials.gov Identifier: NCT01770301

Efficacy and Safety of Bevacizumab (Avastin) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours iray Completed GINECO AGO, BGOG, GOTIC, MITO
Cervical ANZGOG 0902/GOG 0274/RTOG1174

ClinicalTrials.gov Identifier: NCT01414608

OUTBACK TRIAL - A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone Recruiting ANZGOG DGOG, GEICO, GOG, RTOG
Recurrent Ovarian ATALANTE

ClinicalTrials.gov Identifier: NCT02891824

Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab jkurtz Recruitment Pending GINECO AGO, AGO-AUST, BGOG, ISGO
Ovarian AURELIA (GCIG/Roche)

ClinicalTrials.gov Identifier: NCT00976911

A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer bvotan Completed GINECO MITO, NSGO

ClinicalTrials.gov Identifier: NCT01658930

A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer; mplante Recruiting CCTG AGO-AUST, BGOG, DGOG, GINECO, ICORG, KGOG, NCRI
Ovarian CCTG OV.21

ClinicalTrials.gov Identifier: NCT00993655

A phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy dprovencher Completed CCTG GEICO, NCRI
Ovarian CHORUS

ClinicalTrials.gov Identifier: NCT00075712

A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma jledermann Completed NCRI NCRI, SGCTG
Endometrial EN2

ClinicalTrials.gov Identifier: NCT01244789

A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.  mraza Recruiting NSGO BGOG, DGOG, EORTC-GCG, GEICO, ISGO, MaNGO, MITO, NOGGO
Ovarian EWOC-1

ClinicalTrials.gov Identifier: NCT02001272

Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer bvotan Recruiting GINECO AGO, GOTIC, MITO
Recurrent Endometrial FANDANGO

ClinicalTrials.gov Identifier: NTC02730416

ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer mraza Recruiting NSGO BGOG, GINECO, NOGGO, NSGO
Cervical G-GOC-1002

ClinicalTrials.gov Identifier: NCT01048853

Conservative surgery for women with low-risk, early stage cervical cancer kschmeler Recruiting G-GOC GICOM, MITO
Cervical G-GOC-lOOl

ClinicalTrials.gov Identifier: NCT00614211

A Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy Versus Abdominal Radical Hysterectomy in Patients With Early Stage Cervical Cancer The goal of this clinical research study is to compare the long-term outcomes of different surgical methods for the treatment of cervical cancer. The long-term outcome of a total abdominal radical hysterectomy (TARH) will be compared against laparoscopy. In this study, the laparoscopy will be done with or without robotic technology. pramirez Recruiting G-GOC KGOG
Ovarian Clear Cell GCIG/JGOG3017

UMIN Registry ID: UMIN000000499

Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary Completed JGOG GINECO, JGOG, MITO, SGCTG
Recurrent Ovarian GOG 0213

ClinicalTrials.gov Identifier: NCT00565851

Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Recruiting GOG GOG
Recurrent Cervical GOG 240

ClinicalTrials.gov Identifier: NCT00803062

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed GOG GEICO, GOG, MaNGO, NSGO
Cervical GOG 263/KGOG-0801

ClinicalTrials.gov Identifier: NCT01101451

Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery sryu Recruiting GOG GOG, KGOG, RTOG
Ovarian GOG0252

ClinicalTrials.gov Identifier: NCT00951496

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Closed to Recruitment GOG GOG
Ovarian GOG0262

ClinicalTrials.gov Identifier: NCT01167712

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Closed to Recruitment GOG GOG
Cervical/Endometrial GOG233/ACRIN6671

ClinicalTrials.gov Identifier: NCT00416455

Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Closed to Recruitment ACRIN ACRIN, GOG, JGOG, KGOG
Recurrent Ovarian ICON 6 A randomised trial of concurrent cediranib [AZD2171] (with platinum-based chemotherapy) and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer. lfarrelly Completed NCRI GEICO, NCRI, SGCTG
Ovarian ICON 8/ICON8B An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer lfarrelly Recruiting NCRI ANZGOG, GICOM, ICORG, KGOG
Recurrent Maintenance Ovarian ICON 9

ClinicalTrials.gov Identifier: NCT03278717

An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy Pending NCRI ANZGOG, DGOG, GEICO, MaNGO, MITO
Ovarian ICON7 A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in first line treatment of patients with epithelial ovarian cancer. lfarrelly Completed NCRI CCTG, GEICO, GINECO, NCRI, NSGO

ClinicalTrials.gov Identifier: NCT01566240

A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer. lfarrelly Recruiting NCRI GICOM, MaNGO
Ovarian iPocc Trial

ClinicalTrials.gov Identifier: NCT01506856

IntraPeritoneal therapy for Ovarian Cancer with Carboplatin (GOTIC-001 / JGOG3019) Completed GOTIC GOTIC, JGOG
Endometrial KGOG 2015

ClinicalTrials.gov Identifier: NCT01527396

Prospective, Observational Study of Low-risk Criteria for Nod Metastasis in Endometrial Cancer jkim Completed KGOG KGOG, SGOG
Ovarian mEOC


A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer. Completed NCRI DGOG, GINECO, GOG, MaNGO, MITO, NSGO
Cervical MITO CERV 2

ClinicalTrials.gov Identifier: NCT00997009

spignata Closed to Recruitment MITO MITO
Ovarian MITO12

ClinicalTrials.gov Identifier: NCT01061619

Pathway to diagnosis of ovarian cancer: an observational retrospective multicentred study jbryce Completed MITO BGOG, MaNGO, NOGGO
Ovarian MITO7

ClinicalTrials.gov Identifier: NCT00660842

First line weekly carboplatin and paclitaxel versus every 3 weeks carboplatin/paclitaxel in patients with ovarian cancer: phase III multicentre trial spignata Completed MITO GINECO, MaNGO
Recurrent Ovarian MITO8

ClinicalTrials.gov Identifier: NCT00657878

Liposomal doxorubicin stealth vs. carboplatin/paclitaxel in recurrent ovarian cancer patients with platinum-free interval between 6-12 months spignata Completed MITO BGOG, MaNGO, NOGGO
Recurrent Ovarian/Rare NiCCC

ClinicalTrials.gov Identifier: NCT02866370

A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium rglasspool Recruiting SGCTG EORTC-GCG, GINECO, NSGO

ClinicalTrials.gov Identifier: NTC02354131

Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. mraza Completed NSGO
Endometrial NSGO/PALEO

ClinicalTrials.gov Identifier: NTC02730429

A randomized phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer. mraza Recruiting NSGO GEICO, MITO, NOGGO
Ovarian PAOLA-1

ClinicalTrials.gov Identifier: NCT02477644

Platine, Avastin and Olaparib in 1st line Ovarian Cancer iray Completed GINECO AGO, AGO-AUST, BGOG, GOTIC, MITO
Endometrial PORTEC-3 Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma ccreutzberg Closed to Recruitment DGOG CCTG
Cervical RTOG-0724

ClinicalTrials.gov Identifier: NCT00980954

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy ajhingran Recruiting RTOG GOG, RTOG

ClinicalTrials.gov Identifier: NCT03386734

International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer flecuru Recruitment Pending GINECO AGO, GOTIC, KGOG, MaNGO, NCRI
Recurrent Ovarian SOLO-2 (ENGOT-GCIG/AstraZeneca)

ClinicalTrials.gov Identifier: NCT01874353

Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenence Monotherapy in Platinum Sensitive relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy bvotan Completed GINECO AGO, AGO-AUST, BGOG, MITO
Symptom Benefit/Ovarian SYMPTOM BENEFIT Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer? Completed ANZGOG
Cervical TACO

ClinicalTrials.gov Identifier: NCT01561586

Tri-weekly Administration of Cisplatin in Locally Advanced Cervical Cancer sryu Recruiting KGOG
Ovarian Tarceva Trial EORTC 55041

ClinicalTrials.gov Identifier: NCT00263822

A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. Completed EORTC-GCG AGO-AUST, GINECO, MaNGO, NCRI

ClinicalTrials.gov Identifier: NCT03267589

A phase II umbrella trial in patients with relapsed ovarian cancer mraza Recruitment Pending NSGO ANZGOG, BGOG, COGI, GOTIC, KGOG, NOGGO, PMHC, SGCTG